Analysts/Institutional Investor Meet/Con. Call Updates

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 August 8, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Transcript of Post Results Conference Call held on August 6, 2026 Ref: Our Intimation dated August 3, 2026 With reference to the captioned subject, please find enclosed herewith the transcript of the Conference Call held on August 6, 2026. The same is also uploaded on the Company's website i.e. https://www.amanta.co.in/investor-meet You are requested to take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA Company Secretary & Compliance Officer Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 “Amanta Healthcare Limited Q1 FY27 Earnings Conference Call” August 06, 2026 MANAGEMENT: MR. BHAVESH PATEL – CHAIRMAN AND MANAGING DIRECTOR – AMANTA HEALTHCARE LIMITED MR. PARAS MEHTA – CHIEF FINANCIAL OFFICER – AMANTA HEALTHCARE LIMITED MODERATOR: MS. SOUMYA CHHAJED – GO INDIA ADVISORS Page 1 of 18 Amanta Healthcare Limited August 06, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Amanta Healthcare Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note this conference is being recorded. I now hand the conference over to Ms. Soumya Chhajed from Go India Advisors. Thank you, and over to you. Soumya Chhajed: Good morning, everyone, and welcome to Q1 FY27 Earnings Conference Call of Amanta Healthcare Limited. We have on call with us Mr. Bhavesh Patel, Chairman and Managing Director; Mr. Paras Mehta, Chief Financial Officer. We must remind you that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risk pertaining to the business. I now request the management to take us through the same and provide more insight on the quarter gone by. Post that, we'll open the floor for Q&A. Thank you, and over to you, sir. Bhavesh Patel: Namaste and good morning, everyone. And thank you for joining us for Amanta Healthcare Q1 FY27 earnings call. On behalf of the management, I would like to sincerely thank our shareholders, customers, healthcare partners, lenders, and employees for their continued trust and support. The quarter reflects our continued focus on disciplined execution while laying the foundation for the company's next phase of growth. Despite a challenging operating environment marked by inflationary pressure and higher operating cost, we delivered a resilient financial performance and remained focused on executing our long-term strategic priorities. During the quarter, we reported revenue of INR69 crores, up by roughly 5% year-on-year, while maintaining a healthy EBITDA margin of approximately 22%. While the quarter witnessed cost pressures, our focus on operational efficiency enabled us to sustain healthy profitability. Our confidence in the business is driven not just by quarterly performance, but by the strategic investment we are making to strengthen our manufacturing capabilities and product portfolio. Our SteriPort platform, which now contributes around 44% of our revenue, continues to witness strong customer acceptance. Built on advanced ISBM technology, SteriPort offers superiority in terms of sterility, enhanced safety, and lower patient risk compared to conventional packaging solutions. While the existing facility operating at healthy utilization level, we are expanding capacity from 6.6 crore bottles per year to roughly 12 crore bottles per year to cater to increasing demand across high-value therapies such as oncology, critical care, anesthesists, and pediatric. While the SteriPort expansion was originally targeted for commissioning during Q1, the operational delays, mainly due to the delay in the civil construction activity, have shifted the Page 2 of 18 Amanta Healthcare Limited August 06, 2026 commencement to Q2 FY27. We remain confident that this expansion will significantly enhance our manufacturing scale and operating leverage over the coming years. Alongside this, we continue to strengthen our small volume SVP portfolio. This is primarily export-centric business addressing attractive segments such as inhalation solutions, ophthalmics, and preservative-free unit doses. The SVP business contributed around 20% of FY26 revenue, and we expect the new facility to commence operations during Q4 FY27, further expanding our presence in high-margin export market. On the cost optimization front, our 10.8 megawatt captive solar power project has already been commissioned since June '26. It is expected to meaningfully reduce power cost, improve operating margins, and further strengthen our ESG initiatives. With differentiated sterile manufacturing technologies, a growing portfolio of complex products, expanding capacities, and continued focus on operational excellence, we believe Amanta Healthcare is well-positioned to create sustainable long-term value for all stakeholders. Before I conclude, I would once again like to thank all our stakeholders for their continued confidence in Amanta Healthcare. And before I hand over this call to our CFO, Mr. Paras Mehta, I just want to share that SteriPort Line 3 which was being commissioned, we have got the plans approved by FDA on Tuesday and the validation and qualification activities are going on, which are likely to get over by 18th of August, and we intend to take the commercial production in the last week of August, whenever we reach that stage, we will keep you posted. Thank you once again. And now over to our CFO, Shri Paras bhai Mehta. Paras Mehta: Thank you, sir. Good morning, and welcome to all and one to this Q1 result call for Amanta Healthcare. During the quarter, the performance has remained stable. Company has delivered a stable financial performance despite operating in an environment which is characterized by inflationary cost pressures as well as business slowdown due to Iran war situation across all segments. Q1 '27 revenue, as our MD rightly pointed out, despite all this, we could registered 5% year-on- year growth, supported by improved product mix as well as the better price realizations during the quarter. Operational discipline continued to support our profitability. We reported EBITDA of about INR15 crores with EBITDA margin remaining at about 22%. And despite higher raw material price pressure, employee cost, and other operating cost, which already started during the quarter for the new facilities, we could get this result. Looking ahead, we expect the commissioning of our SteriPort expansion by end of current month, followed by SVP facility by end of Q4 '27. Both these is supposed to strengthen our revenue mix towards higher margin products and operating leverage will also expected to help us for the maintaining our current profitability. Page 3 of 18 Amanta Healthcare Limited August 06, 2026 Combined with benefit from captive solar plant and continued cost optimization initiatives, believe that operating leverage will improve meaningfully over coming quarters as we move forward. With that, we conclude our opening remarks and would now be happy to take the questions from shareholders and investors. Thank you once again. Moderator: Thank you, [Showing first 8,000 characters — download PDF for full document]